- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05326308
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma (ARIADNE)
Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL), Marginal Zone Lymphoma (MZL) and Follicular Lymphoma (FL) - a Prospective Multicenter Observational Cohort Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
ARIADNE will collect and analyze data of adult patients with WM, CLL, MZL or FL in need of treatment. The study will explore the medical resource utilization during therapy with zanubrutinib (Brukinsa®). Further aims are to assess effectiveness, safety and tolerability of the treatment as well as treatment satisfaction and biomarkers. These data will be supplemented by the assessment of patient-reported outcomes (PROs)/ health-related quality of life (QoL).
Since treatment options for MW, CLL, MZL or FL are limited and the most important factor is to keep or improve QoL of the patients, there is an urge for real-world clinical data of patients treated with zanubrutinib, especially focusing on patients already treated upfront with a BTK inhibitor, older patients and patients with comorbidities.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Daniel Kummer, Dr.
- Phone Number: +49761152420
- Email: ariadne@iomedico.com
Study Locations
-
-
-
Salzburg, Austria, A-5020
- Recruiting
- Universitätsklinikum Salzburg, Klinik für Innere Medizin III
-
Contact:
- Richard Greil, Prof.
- Phone Number: +435725525800
- Email: r.greil@salk.at
-
-
-
-
Schleswig-Holstein
-
Lübeck, Schleswig-Holstein, Germany, D-23562
- Recruiting
- Lübecker Onkologische Schwerpunktpraxis
-
Contact:
- Jens Kisro, Dr.
- Phone Number: +4945170797226
- Email: jens-kisro@t-online.de
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Waldenström's macroglobulinemia (all treatment lines) OR
- Chronic lymphocytic leukemia (all treatment lines) OR
- Marginal zone lymphoma (≥2 treatment line and at least one anti-CD20 antibody-based previous therapy)
- Follicular lymphoma (≥3 treatment line)
- Signed and dated informed consent form
- Treatment with zanubrutinib according to current SmPC for WM, CLL and MZL
- Treatment with zanubrutinib + obinutuzumab for FL according to current SmPC
- Treatment decision before inclusion into this non-interventional study
- Age ≥18 years.
Exclusion Criteria:
- Contraindications according to SmPC for patients with WM, CLL, MZL or FL
- Participation in an interventional clinical trial during zanubrutinib treatment.
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Waldenström's Macroglobulinemia
75 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
|
according to the Summary of Product Characteristics (SmPC).
Other Names:
|
Chronic Lymphocytic Leukemia
250 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
|
according to the Summary of Product Characteristics (SmPC).
Other Names:
|
Marginal Zone Lymphoma
37 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®)
|
according to the Summary of Product Characteristics (SmPC).
Other Names:
|
Follicular Lymphoma
38 patients (excluding screening failures, patients with off-label use or with violation of inclusion/exclusion criteria identified after treatment start) receiving zanubrutinib (Brukinsa®) in combination with obinutuzumab (Gazyvaro®)
|
according to the Summary of Product Characteristics (SmPC).
Other Names:
according to the Summary of Product Characteristics (SmPC).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medical resource utilization
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency of hospitalizations, i.e. number of hospital stays plus number of emergency unit visits (without hospitalization) per patient
|
During zanubrutinib treatment, up to 5 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Global health-related quality of life (QoL) collected via EORTC QLQ-C30 during course of treatment and follow-up
Time Frame: During zanubrutinib treatment and follow-up, up to 5 years
|
Course of QoL during treatment and follow-up (collected via European Organisation for research and treatment of cancer quality of life in cancer patient questionnaire (EORTC QLQ-C30).
Scoring of the questionnaire will be performed according to the respective manual.
|
During zanubrutinib treatment and follow-up, up to 5 years
|
Global health-related quality of life (QoL) collected via EQ-5D-5L during course of treatment and follow-up
Time Frame: During zanubrutinib treatment and follow-up, up to 5 years
|
Course of QoL during treatment and follow-up (collected via European quality of life 5 dimension 5 level version (EQ-5D-5L)).
Scoring of the questionnaire will be performed according to the respective manual.
|
During zanubrutinib treatment and follow-up, up to 5 years
|
Incidence of (serious) adverse events ((S)AEs)
Time Frame: Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Incidence of (S)AEs; (S)AEs will be summarized by the most recent Medical Dictionary for Regulatory Activities (MedDRA) system organ class and preferred term.
|
Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Incidence of (serious) adverse drug reactions ((S)ADRs)
Time Frame: Start of zanubrutinib treatment until end of study, up to 5 years
|
Incidence of (S)ADRs related to zanubrutinib
|
Start of zanubrutinib treatment until end of study, up to 5 years
|
Incidence of adverse events of special interest (AESIs)
Time Frame: Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Incidence of AESIs
|
Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Time to AESIs
Time Frame: Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
The time to first onset of AESIs.
|
Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Time to neutropenia
Time Frame: Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
The time to first onset of neutropenia grade ≥3 (MedDRA terms: neutropenia and neutrophil count decrease).
|
Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Rate of neutropenia grade ≥3
Time Frame: Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Rate of patients with neutropenia grade ≥3 during zanubrutinib treatment.
Neutropenia incorporates the MedDRA terms: neutropenia and neutrophil count decrease.
|
Start of zanubrutinib treatment until 30 days after end of zanubrutinib treatment
|
Proportion of patients with complete response (CR) or very good partial response (VGPR) (best reported response)
Time Frame: During zanubrutinib treatment, up to 5 years
|
The proportion of patients with a best overall response of CR or VGPR.
|
During zanubrutinib treatment, up to 5 years
|
Progression-free Survival (PFS)
Time Frame: Treatment start with zanubrutinib until end of study, up to 5 years
|
PFS is defined as the time from treatment start until progression or death from any cause, whichever comes first.
|
Treatment start with zanubrutinib until end of study, up to 5 years
|
Overall Survival (OS)
Time Frame: Treatment start with zanubrutinib until end of study, up to 5 years
|
OS is defined as the time from treatment start until death.
|
Treatment start with zanubrutinib until end of study, up to 5 years
|
Time to treatment failure (TTF)
Time Frame: Treatment start with zanubrutinib until end of treatment, up to 5 years
|
TTF is defined as time interval from treatment start to discontinuation of treatment because of disease progression, treatment toxicity, switch of therapy of any reason, and death.
|
Treatment start with zanubrutinib until end of treatment, up to 5 years
|
Frequency of blood product transfusion
Time Frame: During zanubrutinib treatment, up to 5 years
|
The number of patients receiving blood product transfusion, the number of transfusions per patient and the kind of transfusion (e.g., erythrocytes, thrombocytes).
|
During zanubrutinib treatment, up to 5 years
|
Therapy decision making
Time Frame: Baseline
|
Frequency and weighting of distinct parameters affecting therapy choice of the treating physician assessed by project specific questionnaire
|
Baseline
|
Frequency of antibiotic use for prophylactic reasons during zanubrutinib treatment
Time Frame: During zanubrutinib treatment, up to 5 years
|
Proportion of patients with at least one-time antibiotic use for prophylactic reasons during zanubrutinib treatment.
|
During zanubrutinib treatment, up to 5 years
|
Frequency of antibiotic use for treatment of AEs during zanubrutinib treatment
Time Frame: During zanubrutinib treatment, up to 5 years
|
Proportion of patients taking at least one-time antibiotics for treatment of AEs during zanubrutinib treatment.
|
During zanubrutinib treatment, up to 5 years
|
Frequency of antibiotic use in patients with neutropenia during zanubrutinib treatment
Time Frame: During zanubrutinib treatment, up to 5 years
|
Proportion of patients presenting with neutropenia during zanubrutinib treatment taking at least one-time antibiotics.
|
During zanubrutinib treatment, up to 5 years
|
In the WM cohort only: Major response rate (MRR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
MRR is defined as the proportion of patients with a best overall response ≥ PR (partial response)
|
During zanubrutinib treatment, up to 5 years
|
In the WM cohort only: Best response
Time Frame: During zanubrutinib treatment, up to 5 years
|
Best response is defined as best reported response during study treatment CR (complete response) or VGPR (very good partial response).
|
During zanubrutinib treatment, up to 5 years
|
In the WM cohort only: IgM levels
Time Frame: During zanubrutinib treatment, up to 5 years
|
Change of IgM levels until end of zanubrutinib treatment for WM cohort.
|
During zanubrutinib treatment, up to 5 years
|
6-, 12-, 18- and 24-month PFS rate
Time Frame: 6, 12, and 24 months after start of zanubrutinib treatment
|
Percentage of patients without disease progression or death from any cause at 6, 12, and 24 months after start of zanubrutinib treatment.
|
6, 12, and 24 months after start of zanubrutinib treatment
|
6-, 12-, 18- and 24-month OS rate
Time Frame: 6, 12, and 24 months after start of zanubrutinib treatment
|
Percentage of patients alive at 6, 12, and 24 months after start of zanubrutinib treatment.
|
6, 12, and 24 months after start of zanubrutinib treatment
|
WM Cohort: Overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the WM cohort, overall response rate is defined as CR, VGPR and PR (partial response).
|
During zanubrutinib treatment, up to 5 years
|
WM Cohort: Best overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the WM cohort, best overall response rate is defined as CR, VGPR, PR (partial response), MR (minor response), SD (stable disease) or PD (progressive disease).
|
During zanubrutinib treatment, up to 5 years
|
CLL Cohort: Overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the CLL cohort, overall response rate is defined as CR and PR.
|
During zanubrutinib treatment, up to 5 years
|
CLL Cohort: Best overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the CLL cohort, best overall response rate is defined as CR, PR, SD or PD.
|
During zanubrutinib treatment, up to 5 years
|
MZL Cohort: Overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the MZL cohort, overall response rate is defined as CR, pMRD (probable minimal residue disease), PR and rRD (responding residual disease).
|
During zanubrutinib treatment, up to 5 years
|
MZL Cohort: Best overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the MZL cohort, best overall response rate is defined as CR, pMRD, PR, rRD, No change/SD or PD
|
During zanubrutinib treatment, up to 5 years
|
WM Cohort: Change of IgM levels until end of zanubrutinib treatment
Time Frame: Baseline and end of zanubrutinib treatment, up to 5 years
|
Difference between the baseline value and the end of treatment value of the IgM level.
|
Baseline and end of zanubrutinib treatment, up to 5 years
|
Frequency for concomitant medication during zanubrutinib treatment
Time Frame: During zanubrutinib treatment, up to 5 years
|
Substances (WHO-ATC level 2), ongoing status and indication (frequencies)
|
During zanubrutinib treatment, up to 5 years
|
FL Cohort: Overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the FL cohort, overall response rate is defined as CR or PR.
|
During zanubrutinib treatment, up to 5 years
|
FL Cohort: Best overall response rate (ORR)
Time Frame: During zanubrutinib treatment, up to 5 years
|
For the FL cohort, best overall response rate is defined as CR, PR, MR, SD or PD.
|
During zanubrutinib treatment, up to 5 years
|
Time from first diagnosis of WM, CLL, MZL or FL to zanubrutinib treatment start
Time Frame: Baseline
|
Time from first diagnosis of WM, CLL, MZL or FL to zanubrutinib treatment start including timing and duration of possible watch & wait strategy.
|
Baseline
|
Previous therapies
Time Frame: Baseline
|
Key details of previous therapies (including plasmapheresis for WM, transplantations for WM, CLL and FL, radiotherapy for CLL, MZL and FL and surgery for CLL, MZL and FL).
|
Baseline
|
Daily dose of zanubrutinib
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables including the daily dose (mg) will be given using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
FL cohort: Daily dose of obinutuzumab
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables including the daily dose (mg) will be given using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
Dose modifications of zanubrutinib
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including therapy modifications (reduction and increase) with reasons using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
FL cohort: Dose modifications of obinutuzumab
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including therapy modifications (reduction and increase) with reasons using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
Therapy interruptions of zanubrutinib
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including treatment interruptions with reasons as well as reasons for treatment termination.
|
During zanubrutinib treatment, up to 5 years
|
FL cohort: Therapy interruptions of obinutuzumab
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including treatment interruptions with reasons as well as reasons for treatment termination.
|
During zanubrutinib treatment, up to 5 years
|
Dose intensity of zanubrutinib
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including the dose intensity (absolute and relative) using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
FL cohort: Dose intensity of obinutuzumab
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including the dose intensity (absolute and relative) using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
Treatment duration with zanubrutinib
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including the treatment duration will be given using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
FL cohort: Treatment duration with obinutuzumab
Time Frame: During zanubrutinib treatment, up to 5 years
|
Frequency tables will be provided including the treatment duration will be given using descriptive statistics.
|
During zanubrutinib treatment, up to 5 years
|
Subsequent antineoplastic therapies
Time Frame: End of zanubrutinib treatment until end of study, up to 5 years
|
Key details of subsequent antineoplastic therapies after zanubrutinib (including plasmapheresis for WM, stem cell transplantations for WM, CLL and FL, radiotherapy for CLL, MZL and FL and surgery for CLL, MZL and FL): duration (descriptive statistics), number, substances and reason for end of subsequent treatments (frequencies).
|
End of zanubrutinib treatment until end of study, up to 5 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patients' treatment expectation and satisfaction
Time Frame: Baseline, 3 months after treatment start with zanubrutinib, end of treatment
|
Patients' treatment expectation and satisfaction (assessed via project specific questionnaire) will be analyzed by time point, using absolute and relative frequencies.
|
Baseline, 3 months after treatment start with zanubrutinib, end of treatment
|
Physicians' treatment expectation and satisfaction
Time Frame: Baseline, 3 months after treatment start with zanubrutinib, end of treatment
|
Physicians' treatment expectation and satisfaction (assessed via project specific questionnaire) will be analyzed by time point, using absolute and relative frequencies.
|
Baseline, 3 months after treatment start with zanubrutinib, end of treatment
|
Patient management during SARS-Covid-19 pandemic
Time Frame: Baseline and end of zanubrutnib treatment, up to 5 years
|
The patient management during SARS-Covid-19 pandemic (assessed via project specific questionnaire) (patient supervised by oncologist or additionally by family doctor) will be presented by frequency tables.
|
Baseline and end of zanubrutnib treatment, up to 5 years
|
Collection of biomarker test results (according to clinical routine)
Time Frame: Baseline, up to 5 years
|
Number of patients with biomarker testing as well as sample types, test methods and test results of biomarker testing per biomarker will be provided including patients with resistance mechanism testing before treatment decision with zanubrutinib.
Information on the testing of MYD88 and CXCR4 is mandatory.
|
Baseline, up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jens Kisro, Dr., Lübecker Onkologische Schwerpunktpraxis
- Principal Investigator: Richard Greil, Prof., Universitätsklinikum Salzburg, Klinik für Innere Medizin III
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, B-Cell
- Lymphoma, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, Follicular
- Leukemia
- Lymphoma, B-Cell, Marginal Zone
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Obinutuzumab
- Zanubrutinib
Other Study ID Numbers
- IOM-100461
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on Zanubrutinib
-
Zhang Lei, MDRecruitingThrombocytopenia | Antiphospholipid Syndrome | TreatmentChina
-
Fudan UniversityRecruiting
-
Xuanwu Hospital, BeijingRecruitingNeuromyelitis OpticaChina
-
Zhang LeiRecruitingImmune Thrombocytopenia | TreatmentChina
-
Matthew C. BakerStanford UniversityRecruiting
-
Stichting Hemato-Oncologie voor Volwassenen NederlandNot yet recruitingLymphomaNorway, Netherlands, Denmark, Belgium
-
The First Affiliated Hospital of Soochow UniversityRecruitingUntreated Mantle Cell LymphomaChina
-
Huazhong University of Science and TechnologyRecruitingDiffuse Large B Cell LymphomaChina
-
UMC UtrechtBeiGeneNot yet recruitingMonoclonal Gammopathy of Uncertain SignificanceNetherlands
-
Fudan UniversityRecruitingMantle Cell Lymphoma | Maintenance TherapyChina